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Case Report18F-PSMA-1007 PET/CT Detects
Micrometastases in a Patient With Biochemically
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 To date, several radioactive tracers for imaging primary
and recurrent prostate cancer are undergoing active
investigation.
 In this case report ﬂuorine-18 (18F)eprostate-speciﬁc
membrane antigen (PSMA)-1007 positron emission
tomography (PET)/computed tomography imaging
was performed, to our knowledge, for the ﬁrst time in a
patient with biochemical recurrence (prostate-speciﬁc
antigen [PSA] 0.08 mg/L) after radical prostatectomy
and adjuvant radiation.
 Seventeen lymph nodes with increased tracer uptake
along the retroperitoneum and iliac arteries were
detected. Therefore, early treatment with intermittent
androgen deprivation was initiated instead of locore-
gional salvage therapy.
 Hence, 18F-PSMA-1007 PET imaging at very low PSA
levels provided critical information to correctly restage
disease.Clinical Genitourinary Cancer, Vol. 15, No. 3, e497-9 ª 2016 The Author(s). Published by Elsevier Inc. This is an open access
article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Radiotracer-labeled prostate-speciﬁc membrane antigen (PSMA)
targeting positron emission tomography (PET) revolutionized
prostate cancer imaging. In the following case study we evaluated
the new ﬂuorine-18 (18F)-PSMA-1007 tracer, to our knowledge, for
the ﬁrst time, in a patient with biochemical recurrence.
Case
In August 2016, a 79-year-old man was referred to our clinic,
with the request for restaging of prostate cancer because of slowly1Department of Nuclear Medicine
2Department of Urology, University Hospital Heidelberg, Heidelberg, Germany
3Department of Nuclear Medicine, Yonsei University Severance Hospital, Seoul, South
Korea
4Division of Radiopharmaceutical Chemistry, German Cancer Research Centre, Hei-
delberg, Germany
Submitted: Dec 13, 2016; Accepted: Dec 22, 2016; Epub: Dec 29, 2016
Address for correspondence: Frederik L. Giesel, MD, Department of Nuclear Medi-
cine, University Hospital Heidelberg, Im Neuenheimer Feld 400, Heidelberg 69120,
Germany
Fax: þ49-6221-56-8672; e-mail contact: frederik@egiesel.com
1558-7673/ª 2016 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.clgc.2016.12.029rising prostate-speciﬁc antigen (PSA) levels 9 years after radical
prostatectomy and adjuvant radiotherapy. Technetium 99m-methyl
diphosphonate whole body bone scan, computed tomography (CT)
and magnetic resonance imaging (MRI) of the abdomen and pelvis
revealed no remarkable pathological ﬁnding.
In March 2007, the patient was diagnosed with intermediate-risk
prostate cancer and prostatectomy was performed, which presented
with positive margins (pT3a, N0, M0; Gleason score 4þ3; positive
margins with tumor inﬁltration at the apical left site of the prostate).
Adjuvant radiotherapy was administered to the prostatic bed with 60
Gy in 30 fractions. The PSA level decreased from5.3 before to 0.03 ng/
mL after surgery. Regular laboratory tests showed a gradual increase of
PSA levels up to 0.08 ng/mL in July 2016, suggesting vital tumor tissue
somewhere that might be amenable to salvage therapy such as stereo-
tactic body radiation or high-intensity focused ultrasound, if found.
After multidisciplinary discussion we decided to perform PET/CT
imaging with the 18F-labeled PSMA-targeted radioligand PSMA-
1007, an experimental molecular PET radiotracer, which has been
described to have higher detection rates compared with standard
morphological imaging modalities such as CT and MRI.1Clinical Genitourinary Cancer June 2017 - e497
Figure 1 (A) Fluorine-18 (18F)-Prostate-Speciﬁc Membrane Antigen (PSMA)-1007 Maximum Intensity Projection-Positron Emission
Tomography (PET)/Computed Tomography (CT) in a Patient With Biochemical Recurrence After Prostatectomy Presented
Lymph Nodes With Increased 18F-PSMA-1007 Uptake, Consistent With Lymph Node Metastases. All 18F-PSMA-1007 Positive
Lymph Nodes (B) Were Under CT-Morphological Detection Rate; in Contrast All Lymph Nodes Presented a High PSMA-1007
Uptake in PET
Abbreviation: SUV ¼ standardized uptake value.
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18F-PSMA-1007 PET/CT and MicrometastasesThe patient underwent 18F-PSMA-1007 PET/CT imaging and,
surprisingly, 17 lymph nodes were detected with increased PSMA
uptake (n ¼ 17; median ¼ standardized uptake value (SUV)
max ¼ 7.71; maximum ¼ 18.8/minimum ¼ 3.2) along the ret-
roperitoneum and iliac arteries, which were consistent with pros-
tate cancer recurrence. An automated segmented volumetric
analysis was applied to measure the sizes of 18F-PSMA-1007-
positive lymph nodes. All were below the morphological detec-
tion limit and thus could be not considered as lymph node
metastasis according to Response Evaluation Criteria in Solid
Tumors criteria (n ¼ 17; median ¼ 4.6 mm; maximum ¼ 6.6/
minimum ¼ 3.2 mm; Figure 1). Because of 18F-PSMA-1007-
positive prostate cancer spread along the lymph nodes, the patient
was classiﬁed as M1. Therefore, early treatment with intermittent
androgen deprivation was initiated instead of locoregional salvage
therapy.2,3
Discussion
In patients with biochemical recurrence localization of recurrent
prostate cancer is essential for further therapy planning. Conventional- Clinical Genitourinary Cancer June 2017cross-sectional imaging or bone scintigraphy shows only limited
detection rates in these cases, especially at low serum PSA values.4
Therefore, several radioactive tracers for improved imaging of recur-
rent but also primary prostate cancer are under active investigation.5-9
PSMA radioligands have been presented so far as the most sensitive
and speciﬁc with regard to prostate cancer detection, in particular in
high-risk prostate cancer patients. For themost commonly used 68Ga-
PSMA-11 radioligand, detection rates of 50% to 57.9% are described
in patients with biochemical recurrence and serum PSA levels < 0.5
ng/mL.10,11 Nevertheless, 18F-PSMA-1007 does have some advan-
tageous characteristics: 18F is produced by a cyclotron facilitating a
higher available amount of radioisotope compared with generator-
capacity bound 68Ga-PSMA. Its low positron emission energy re-
sults in a higher image resolution and its partially hepatobiliary
elimination might ease the evaluation of the prostate bed and
pelvis.12,13 In this case report 18F-PSMA-1007 was used, to our
knowledge, for the ﬁrst time, in a patient with biochemically recur-
rent prostate cancer and 17 lymph nodes were detected with increased
PSMA uptake at a PSA serum level of 0.08 ng/mL implying major
potential for staging recurrent prostate cancer.
Frederik L. Giesel et alConclusion
Novel 18F-PSMA-1007 PET imaging at very low PSA levels
provided critical information to correctly restage disease and to
discuss appropriate treatment options.Acknowledgments
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